Low prognostic nutritional index predicts poor outcome in diffuse large B-cell lymphoma treated with R-CHOP
Low prognostic nutritional index predicts poor outcome in diffuse large B-cell lymphoma treated with R-CHOP
复制标题
DOI：
10.1007/s12185-016-2052-9
复制
发表时间：
2016-10-01
影响因子：
2.1
通讯作者：
Feng, Ru
中科院分区：
文献类型：
--
作者：
Zhou, Qinjun;Wei, Yongqiang;Feng, Ru
预后营养指数（PNI），基于血清白蛋白浓度和绝对外周淋巴细胞计数，已被用来预测各种肿瘤的生存。PNI是否可以预测弥漫性大B细胞淋巴瘤（DLBCL）患者的预后仍不清楚。我们回顾性分析了253例新诊断的DLBCL患者。PNI计算方法为：白蛋白（g/L）+ 5 x总淋巴细胞计数x 10（9）/L。根据受试者工作特征（ROC）曲线将所有患者分为低、高两组。低PNI与更不利的临床特征相关（p < 0.05）。低PNI患者的无事件生存期（EFS）和总生存期（OS）更差（EFS，p = 0.001; OS，p < 0.001）。对于接受R-CHOP治疗的患者，PNI被证明是生存预测（EFS，p = 0.001; OS，p < 0.001），而在接受CHOP化疗的DLBCL患者中没有发现显著效果（EFS，p = 0.496; OS，p = 0.125）。多因素分析显示，低PNI是OS和EFS的独立不良预测因素，尤其是在接受R-CHOP治疗的DLBCL患者中。总之，这项研究表明，PNI是一个有效的预后因子DLBCL患者与R-CHOP治疗。
Prognostic nutritional index (PNI), based on serum albumin concentration and the absolute peripheral lymphocyte count, has been used to predict survival in various tumors. Whether PNI can predict prognosis in patients with diffuse large B-cell lymphoma (DLBCL) remains unknown. We retrospectively analyzed 253 patients with newly diagnosed DLBCL in the present study. The PNI was calculated as: albumin (g/L) + 5 x total lymphocyte count x 10(9)/L. All patients were divided in low and high groups according to the analysis of receiver operating characteristic (ROC) curve. Low PNI was associated with more unfavorable clinical features (p < 0.05). Patients with low PNI tended to have worse event-free survival (EFS) and overall survival (OS) (EFS, p = 0.001; OS, p < 0.001). For patients treated with R-CHOP, PNI proved to be predictive for survival (EFS, p = 0.001; OS, p < 0.001), while no significant effect was found in DLBCL patients who received CHOP chemotherapy (EFS, p = 0.496; OS, p = 0.125). Multivariate analysis showed that low PNI is an independent adverse predictor of OS and EFS, especially in DLBCL patients treated with R-CHOP. In conclusion, this study suggests that PNI is an effective prognostic factor in DLBCL patients treated with R-CHOP.